SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today announced it will report third quarter 2006 financial results after the NASDAQ Global Market closes on Wednesday, October 25, 2006. That same afternoon, Jack Lief, Arena’s President and Chief Executive Officer, and Robert E. Hoffman, Arena’s Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the third quarter 2006 financial results and to provide a corporate update.
The conference call may be accessed by dialing 800.573.4842 for domestic callers and 617.224.4327 for international callers. Please specify to the operator that you would like to join the “Arena Third Quarter 2006 Earnings Call.” The conference call will be webcast live under the investor relations section of Arena’s website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena’s most advanced product candidate, lorcaserin hydrochloride, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena’s broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated for serious diseases and disorders independently and with our partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. CART(TM) is an unregistered service mark of the company. “APD” is an abbreviation for Arena Pharmaceuticals Development.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena’s strategy and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena’s planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; the results of preclinical studies or clinical trials may not be predictive of future results; the timing, success and cost of Arena’s research and development; Arena’s ability to partner lorcaserin hydrochloride, APD125 or other of its compounds or programs; Arena’s ability to obtain additional financing; Arena’s ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena’s collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena’s forward-looking statements are disclosed in Arena’s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contacts: Jack Lief Carolyn Wang President and CEO WeissComm Partners Media Relations 415.946.1065 David Walsey Director, Corporate Communications Arena Pharmaceuticals 858.453.7200, ext. 1682 www.arenapharm.com
Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and CEO, or David Walsey, Director,Corporate Communications, both of Arena Pharmaceuticals, +1-858-453-7200,ext. 1682; or Media Relations, Carolyn Wang of WeissComm Partners,+1-415-946-1065, for Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com/
